Eko Analysis Software vs AVIEW

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Eko Health
VS
by Coreline Soft Co.

AI Verdict

These tools offer adjacent, rather than direct, comparability. Eko Analysis Software focuses on early detection of cardiovascular diseases like heart murmurs and atrial fibrillation through digital stethoscope and ECG analysis, suitable for point-of-care assessment. AVIEW, conversely, is an imaging-based platform primarily for lung conditions, though it includes coronary artery calcification scoring from CT scans, making it more suited for detailed radiological diagnosis.

Choose Eko Analysis Software if…

Choose Eko Analysis Software if your primary need is real-time, AI-assisted auscultation for early detection of heart murmurs and atrial fibrillation at the point of care or during telehealth consultations. This tool is ideal for clinicians seeking to quickly screen patients for common cardiovascular conditions using a digital stethoscope, with the ability to record, visualize, and securely store heart sounds and ECGs.

View Eko Analysis Software →

Choose AVIEW if…

Choose AVIEW if your practice requires advanced AI-driven analysis of CT scans for comprehensive detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification. This platform is best suited for radiologists and specialists who need detailed quantitative assessments, automated segmentation, and workflow integration to enhance diagnostic precision and manage patient follow-ups efficiently across multiple pulmonary and cardiac conditions.

View AVIEW →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Eko Analysis Software AVIEW
Pricing Unknown Subscription; one-off payment
Deployment Unknown Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)
BAA Available Yes AI-estimated Unknown
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Analysis Software

Eko Analysis Software integrates with digital stethoscopes and a mobile app, offering a freemium model that suggests a focus on ease of adoption and direct clinician use. The mobile-first approach and basic free features likely contribute to a more intuitive and accessible user experience for individual practitioners. AVIEW, designed for radiologists analyzing complex CT scans, implies a more specialized and potentially steeper learning curve.

Clinical Value

AVIEW

While both tools offer significant, FDA-cleared clinical value in their respective specialties, AVIEW provides comprehensive multi-disease analysis from a single CT scan for lung cancer, COPD, and coronary artery calcification, including ILD pattern analysis. This breadth and depth of diagnostic insight from one imaging modality offer a broader clinical impact compared to Eko's point-of-care cardiovascular screening.

Pricing & Value

Eko Analysis Software

Eko Analysis Software's freemium model allows basic app features for free, with a subscription required for full AI-powered detection and advanced functionalities. This offers a low barrier to entry and allows users to experience core benefits before committing to a paid plan. AVIEW's subscription or one-off payment model, based on installations and users, is typical for enterprise software but lacks the initial accessibility of a freemium offering.

Enterprise Readiness

AVIEW

AVIEW offers extensive deployment flexibility, including cloud, hybrid, on-premise, and virtualized solutions, along with explicit features for workflow automation and integration with PACS/RIS/CIS. This robust integration capability and diverse deployment options make it highly adaptable for large-scale hospital and imaging center environments, surpassing Eko's cloud-based, mobile-centric approach for enterprise-level IT infrastructure.

Innovation

AVIEW

AVIEW's comprehensive AI platform for multi-disease analysis (lung cancer, COPD, CAC, ILD) from a single CT scan, coupled with automated segmentation and 3D visualizations, represents a higher degree of innovation in complex diagnostic imaging. Eko innovates by bringing AI to point-of-care auscultation, but AVIEW's multi-faceted approach to complex imaging data stands out for its diagnostic depth and efficiency.

Support & Docs

Eko Analysis Software

Eko Analysis Software offers a more robust and publicly accessible suite of support and documentation, including detailed user manuals, quick start guides, a comprehensive online help center with FAQs, troubleshooting tips, video tutorials, and direct contact channels. While AVIEW mentions a customer service team, Eko provides more extensive self-help and educational resources for its user base.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Eko Analysis Software AVIEW
Name Eko Analysis Software AVIEW
Company Eko Devices Coreline Soft Co.
Primary Clinical Focus Cardiovascular diseases (heart murmurs, atrial fibrillation) Lung cancer, COPD, and coronary artery calcification from CT scans
Key Features (Examples) FDA-cleared AI for heart murmur detection, FDA-cleared AI for atrial fibrillation (AFib) detection, Recording, playback, and annotation of heart sounds and ECGs AI-powered lung nodule detection and characterization, Emphysema quantification and low attenuation area (LAA) analysis, Coronary artery calcium (CAC) scoring

Videos

Demos, reviews, and walkthroughs featuring Eko Analysis Software and AVIEW.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Eko Analysis Software is an FDA-cleared AI-powered tool designed to assist clinicians in the early detection of cardiovascular diseases like heart murmurs and atrial fibrillation, as well as normal sinus rhythm, using digital stethoscopes and mobile app integration. In contrast, AVIEW is an AI platform that offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans.
Eko Analysis Software integrates with Eko's digital stethoscopes and mobile app to analyze heart sounds (phonocardiograms) and ECG tracings. AVIEW, on the other hand, processes medical images, specifically CT scans, for its AI-driven diagnostic solutions.
Eko Analysis Software operates on a freemium model, where basic Eko App features are free, but an Eko+ membership or paid subscription is required for full AI-powered detection capabilities, saving recordings, patient profiles, and PDF reports. AVIEW is available through a subscription or a one-off payment, with pricing typically based on the number of installations or users.
Eko Analysis Software provides FDA-cleared AI for heart murmur detection, atrial fibrillation (AFib) detection, and normal sinus rhythm detection, along with the calculation of cardiac time intervals. AVIEW offers AI-powered lung nodule detection and characterization (including size, volume, type, location, and Lung-RADS score), emphysema quantification, coronary artery calcium (CAC) scoring (Agatston, volume, mass score, and risk stratification), and Interstitial Lung Disease (ILD) pattern analysis.
Eko Analysis Software integrates with Eko's digital stethoscopes and mobile app for wireless auscultation, recording, playback, and secure cloud-based storage of recordings. AVIEW emphasizes workflow automation and integration with Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and Clinical Information Systems (CIS), as well as follow-up registration and nodule matching for serial CT scans.

Backers

Who funded each tool's parent company.

Eko Analysis Software

AI Tool Finder
AI-powered search. Results may not be comprehensive.